Domů › Trojně negativní rakovina prsu › Massachusetts › Boston
Klinické studie Trojně negativní rakovina prsu v Boston, MA
26 studií pro Trojně negativní rakovina prsu hledá účastníky v lokalitách v Boston a okolí (do cca 30 mil). Otevřete studii a zjistěte, kdo se může zapojit a jak kontaktovat tým studie.
Oficiální text studie (anglicky)
Hledáte účastníky pro studii? Zvýrazněte ji nahoře na této stránce – $99 na 30 dní →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Probíhá náborFáze 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Probíhá náborFáze 1
- Dana Farber Cancer Institute, Boston
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Probíhá náborFáze 3
- Massachusetts General Hospital Cancer Center ( Site 0091), Boston
- Dana Farber Cancer Institute ( Site 0090), Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer
Probíhá nábor
- Massachusetts General Hospital, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Probíhá náborFáze 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Probíhá náborFáze 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Probíhá náborFáze 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Probíhá náborFáze 2/3
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Probíhá náborFáze 2
- Dana-Farber Cancer Institute, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Probíhá náborFáze 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Probíhá náborFáze 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan In TNBC
Probíhá náborFáze 2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Probíhá náborFáze 1
- Dana-Farber Cancer Institute, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Probíhá náborFáze 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Probíhá náborFáze 2
- Dana-Farber Cancer Institute, Boston
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Probíhá náborFáze 2
- Dana Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Probíhá náborFáze 1
- Dana Farber Cancer Institute, Boston
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Probíhá náborFáze 1
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Probíhá náborFáze 1/2
- Massachusetts General Hospital, Boston
Studie Trojně negativní rakovina prsu v jiných městech
- Houston, TX42 studií
- New York City, NY31 studií
- Nashville, TN28 studií
- Los Angeles, CA27 studií
- San Antonio, TX23 studií
- St. Louis, MO21 studií
- Atlanta, GA20 studií
- Arlington, VA20 studií
- Dallas, TX18 studií
- Chicago, IL16 studií
- Columbus, OH16 studií
- Tampa, FL15 studií
Další studie v Boston
- Rakovina prsu111 studií
- Nemalobuněčný plicní karcinom90 studií
- Rakovina (všechny typy)86 studií
- Kolorektální karcinom63 studií
- Metastatický karcinom63 studií
- Rakovina plic62 studií
- Rakovina vaječníků61 studií
- Rakovina prostaty59 studií
- Deprese52 studií
- Rakovina endometria50 studií
- Srdeční selhání44 studií
- Akutní myeloidní leukemie44 studií
Zdroj: ClinicalTrials.gov, data načtena 5. 10. 2026. Každá studie má vlastní kritéria způsobilosti; o účasti rozhoduje tým studie.